Powder Alloy Development for Additive Manufacturing, AI for Material Allowables in Additive Manufacturing.

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Chemicals industry for Monday, February 02, 2026. Let’s take a ...